The feasibility and safety of Algisyl-LVR™ as a method of left ventricular augmentation in patients with dilated cardiomyopathy: initial first in man clinical results
Lee RJ, Hinson A, Bauernschmitt R, Matschke K, Fang Q, Mann DL, Dowling R, Schiller N, Sabbah HN. The feasibility and safety of Algisyl-LVR as a method of left ventricular augmentation in patients with dilated cardiomyopathy: Initial first in man clinical results. Int J Cardiol. Jul 2 2015;199:18-24.
International journal of cardiology
BACKGROUND: A tissue engineering approach to augment the left ventricular wall has been suggested as a means to treat patients with advanced heart failure. This study evaluated the safety and feasibility of Algisyl-LVR™ as a method of left ventricular augmentation in patients with dilated cardiomyopathy undergoing open-heart surgery.
METHODS AND RESULTS: Eleven male patients (aged 44 to 74years) with advanced heart failure (NYHA class 3 or 4), a left ventricular ejection fraction (LVEF) of
CONCLUSIONS: Administration of Algisyl-LVR to patients with advanced HF at the time of cardiac surgery is feasible and safe; warranting continued development of Algisyl-LVR as a potential therapy in patients with advanced HF.
Medical Subject Headings
Adolescent; Adult; Aged; Alginates; Cardiac Surgical Procedures; Cardiomyopathy, Dilated; Echocardiography; Electrocardiography, Ambulatory; Feasibility Studies; Female; Follow-Up Studies; Heart Ventricles; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Injections; Male; Middle Aged; Stroke Volume; Time Factors; Tissue Engineering; Treatment Outcome; Ventricular Function, Left; Young Adult